Last reviewed · How we verify

Atropine Ophthalmic 0.5%

Erasmus Medical Center · Phase 3 active Small molecule

Atropine Ophthalmic 0.5% is a Anticholinergic agent / Muscarinic antagonist Small molecule drug developed by Erasmus Medical Center. It is currently in Phase 3 development for Myopia control in children (Phase 3), Cycloplegia for refraction, Pupil dilation for ophthalmic examination.

Atropine blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation.

Atropine blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation. Used for Myopia control in children (Phase 3), Cycloplegia for refraction, Pupil dilation for ophthalmic examination.

At a glance

Generic nameAtropine Ophthalmic 0.5%
SponsorErasmus Medical Center
Drug classAnticholinergic agent / Muscarinic antagonist
TargetMuscarinic acetylcholine receptors (M1-M5, primarily M1 and M3)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

Atropine is an anticholinergic agent that competitively antagonizes muscarinic receptors on the iris sphincter muscle and ciliary muscle. This prevents parasympathetic-mediated pupil constriction and accommodation, resulting in mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation). In the context of myopia control, atropine may work by reducing accommodation-induced axial elongation of the eye.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Atropine Ophthalmic 0.5%

What is Atropine Ophthalmic 0.5%?

Atropine Ophthalmic 0.5% is a Anticholinergic agent / Muscarinic antagonist drug developed by Erasmus Medical Center, indicated for Myopia control in children (Phase 3), Cycloplegia for refraction, Pupil dilation for ophthalmic examination.

How does Atropine Ophthalmic 0.5% work?

Atropine blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation.

What is Atropine Ophthalmic 0.5% used for?

Atropine Ophthalmic 0.5% is indicated for Myopia control in children (Phase 3), Cycloplegia for refraction, Pupil dilation for ophthalmic examination.

Who makes Atropine Ophthalmic 0.5%?

Atropine Ophthalmic 0.5% is developed by Erasmus Medical Center (see full Erasmus Medical Center pipeline at /company/erasmus-medical-center).

What drug class is Atropine Ophthalmic 0.5% in?

Atropine Ophthalmic 0.5% belongs to the Anticholinergic agent / Muscarinic antagonist class. See all Anticholinergic agent / Muscarinic antagonist drugs at /class/anticholinergic-agent-muscarinic-antagonist.

What development phase is Atropine Ophthalmic 0.5% in?

Atropine Ophthalmic 0.5% is in Phase 3.

What are the side effects of Atropine Ophthalmic 0.5%?

Common side effects of Atropine Ophthalmic 0.5% include Blurred vision, Photophobia, Ocular irritation, Systemic anticholinergic effects (rare with topical use).

What does Atropine Ophthalmic 0.5% target?

Atropine Ophthalmic 0.5% targets Muscarinic acetylcholine receptors (M1-M5, primarily M1 and M3) and is a Anticholinergic agent / Muscarinic antagonist.

Related